Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.

JAMA network open - 2 Dec 2024

Lin Chien-Yu, Chang Wei-Ting, Su Po-Lan, Kuo Chin-Wei, Yang Jen, Lin Chien-Chung, Lin Sheng-Hsiang

Abstract excerpt

Importance: Although it has been reported that osimertinib mesylate provides better survival benefits compared with first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), it remains unclear whether osimertinib is associated with more cancer therapy-related cardiac events (CTRCEs) compared with other EGFR TKIs, as does the extent of the association these adverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Taiwan

Source

Open in PubMed Open full text

Identifiers

PMID: 39636639
DOI: 10.1001/jamanetworkopen.2024.48364
PMCID: PMC11621985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.PMID 39636639Read ↗

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.Semantic proximity Read ↗

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.Semantic proximity Read ↗

Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).Semantic proximity Read ↗

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read ↗

Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.Semantic proximity Read ↗

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportSemantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Successful Management of Osimertinib-Induced Heart Failure.Semantic proximity Read ↗

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.Semantic proximity Read ↗

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor OsimertinibSemantic proximity Read ↗

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.